Acrivon Therapeutics (ACRV) vs Medicinova (MNOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed Acrivon Therapeutics (ACRV) over the past year, gaining 26.2% versus a loss of 0.5%. Acrivon Therapeutics is the larger company by market cap ($82.5 million vs $76.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | MNOV |
|---|---|---|
| Share price | $1.93 | $1.55 |
| Market cap | $82.49M | $76.29M |
| 1-day change | +2.94% | +0.65% |
| YTD return | -22.41% | +17.56% |
| 1-year return | -0.53% | +26.23% |
| 5-year return | — | -59.69% |
| EPS (TTM) | $-1.88 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $3.90 |
| 52-week low | $1.27 | $1.17 |
| Distance from 52-week high | -45.93% | -60.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +497.40% | +432.26% |
| Average volume | 356.18K | 322.57K |
| Shares outstanding | 42.85M | 49.22M |
| Employees | 74 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed ACRV by 26.8 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
ACRV vs MNOV FAQ
Which is bigger, Acrivon Therapeutics or Medicinova?
Acrivon Therapeutics (ACRV) is larger, with a market capitalization of $82.49M compared with $76.29M for Medicinova (MNOV).
Which stock has performed better over the past year, ACRV or MNOV?
MNOV returned +26.23% over the past 12 months, compared with -0.53% for ACRV (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Medicinova in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.